Results from a recent study reveal insured Americans believe health insurance is not living up to providing affordable and accessible healthcare.
In the fourth installment of the Patient Experience Survey (PES) from PhRMA/Ipsos, it was found coverage and affordability continue to fall short for many insured Americans who need access to care.
Conducted April 4 to 17 this year by Ipsos using the probability-based KnowledgePanel®, the survey is based on 5,152 adults aged 18 or older. The survey included 3,443 insured respondents who reported taking prescription medicines and 4,823 respondents who reported being insured.
Researchers designed the survey to explore the experiences and barriers patients face in accessing healthcare and prescription medicines.
Results reveal insured Americans believe health insurance is not living up to providing affordable and accessible healthcare. For example, many insured Americans worry insurance may not cover a medicine their doctor prescribes, and some report difficulty accessing medication because of insurance barriers. Out-of-pocket healthcare costs are also a significant concern for the insured.
Those in this category said they are more worried about their ability to afford their healthcare out-of-pocket costs (57%) than they are about expenses like the costs of healthy food (45%) or transportation (40%).
Other key findings in the survey include:
Data found participants believe potential solutions to combat these concerns can address out-of-pocket costs and insurance barriers.
Some of these solutions include ensuring more predictability in healthcare, so folks know how much they will pay for things such as prescription drugs every month.
Two Opdivo Updates from Bristol Myers Squibb
May 14th 2024First approved by the U.S. Food and Drug Administration (FDA) in 2014, Opdivo has multiple indications across various types of cancer, including NSCLC, melanoma, renal cell carcinoma, Hodgkin lymphoma, squamous cell carcinoma of the head and neck, and urothelial carcinoma.
Read More
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More